Huang Z, He J, Su J, Ou Z, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in
Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study. Vaccine 2020 Nov 22. pii: S0264-410X(20)31434.
PMID: 33239228